The current US and European guidelines recommend FXa inhibitors and direct thrombin inhibitor over warfarin for stroke prevention in high-risk patients with atrial fibrillation.13,14 FXa inhibitors do not require therapeutic monitoring and are associated with fewer adverse effects and lower rates of bleeding complications, particularly hemorrhagic stroke, than warfarin. The gene discussed is F10; the disease is hemorrhagic stroke.